Arthur F Kavanaugh
Overview
Explore the profile of Arthur F Kavanaugh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1961
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A
RMD Open
. 2018 Apr;
4(1):e000659.
PMID: 29670761
Objectives: To evaluate the effect of certolizumab pegol (CZP) on work and household productivity, and on participation in family, social and leisure activities in patients with axial spondyloarthritis (axSpA), including...
2.
Burmester G, Kaeley G, Kavanaugh A, Gabay C, MacCarter D, Nash P, et al.
RMD Open
. 2017 Sep;
3(2):e000465.
PMID: 28955494
Background: Treatment of rheumatoid arthritis (RA) with a combination of methotrexate (MTX)+adalimumab (ADA) is more effective than ADA monotherapy. We assessed the toxicity of different doses of MTX and treatment...
3.
Fleischmann R, Huizinga T, Kavanaugh A, Wilkinson B, Kwok K, DeMasi R, et al.
RMD Open
. 2016 Aug;
2(2):e000262.
PMID: 27493790
Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of...
4.
Coates L, Ritchlin C, Kavanaugh A
J Rheumatol
. 2014 Jun;
41(6):1237-9.
PMID: 24882861
Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by the association of arthritis and periarticular inflammation in patients with psoriasis. In addition to a heterogeneous and variable clinical...
5.
Choy E, Kavanaugh A, Jones S
Nat Rev Rheumatol
. 2013 Feb;
9(3):154-63.
PMID: 23419427
The introduction of biologic agents to clinical practice has had a major bearing on the treatment of patients with chronic inflammatory diseases such as rheumatoid arthritis. These drugs have the...
6.
Strober B, Cather J, Cohen D, Crowley J, Gordon K, Gottlieb A, et al.
Dermatol Ther (Heidelb)
. 2012 Dec;
2(1):2.
PMID: 23205325
Introduction: Clinicians may be confronted with difficult-to-treat psoriasis cases for which there are scant data to rely upon for guidance. To assist in managing such patients, who are typically excluded...
7.
Strober B, Cather J, Cohen D, Crowley J, Gordon K, Gottlieb A, et al.
Dermatol Ther (Heidelb)
. 2012 Dec;
2(1):1.
PMID: 23205324
Introduction: Traditional clinical trials in psoriasis exclude a significant proportion of patients with complex disease and comorbidities. A consensus panel of 14 experts in the field of psoriasis was formed...
8.
Pavelka K, Kavanaugh A, Rubbert-Roth A, Ferraccioli G
Rheumatology (Oxford)
. 2012 Jun;
51 Suppl 5:v12-21.
PMID: 22718922
Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure to achieve adequate disease control in many patients, even with combination therapy, has spurred...
9.
Singh J, Furst D, Bharat A, Curtis J, Kavanaugh A, Kremer J, et al.
Arthritis Care Res (Hoboken)
. 2012 Apr;
64(5):625-39.
PMID: 22473917
No abstract available.
10.
Kavanaugh A, Mayer L, Cush J, Hanauer S
Am J Med
. 2011 May;
124(4 Suppl):e1-18.
PMID: 21531240
No abstract available.